These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20514109)

  • 41. The effectiveness of low-dose maintenance i.v. iron therapy: a dialysis facility's experience.
    Peter J; Finkelstein F
    Nephrol Nurs J; 2006; 33(1):71-4, 90. PubMed ID: 16538930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Chronic kidney failure, anemia and erythropoietin].
    Sulková S
    Cas Lek Cesk; 1990 May; 129(18):545-9. PubMed ID: 2350772
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 44. Iron replacement and supplementation in patients with chronic kidney disease.
    Wazny LD; Raymond CB
    CANNT J; 2011; 21(4):26-30; quiz 31-2. PubMed ID: 22324122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pathophysiological characteristics of anemia in patients periodically dialyzed].
    Antonov S
    Vutr Boles; 1985; 24(2):13-8. PubMed ID: 3898583
    [No Abstract]   [Full Text] [Related]  

  • 46. [A study of anemia in 86 patients on hemodialysis (author's transl)].
    Serra A; Camps J; Morlans M; Olmos A; Carrera A; Soriano B; Rodríguez JA; Pelegrí A; Bartolomé J; Piera L
    Med Clin (Barc); 1981 May; 76(10):439-43. PubMed ID: 7242164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Changes in iron metabolism and erythropoietin requirements after the switch from ferric gluconate to iron saccharose. Is it worth the increased expense?].
    Rodríguez Palomares JR; Fanlo B; Albarracín C; Junquera E
    Nefrologia; 2003; 23(2):181-2. PubMed ID: 12778887
    [No Abstract]   [Full Text] [Related]  

  • 49. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 50. [The abnormalities of blood cells in chronic kidney failure with long-term dialysis].
    Narita M; Shibata A
    Nihon Rinsho; 1992 Jan; 50 Suppl():763-70. PubMed ID: 1578764
    [No Abstract]   [Full Text] [Related]  

  • 51. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease.
    Blaustein DA; Schwenk MH; Chattopadhyay J; Singh H; Daoui R; Gadh R; Avram MM
    Kidney Int Suppl; 2003 Nov; (87):S72-7. PubMed ID: 14531777
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin.
    Jones-Lecointe A; Green PJ; Lee HA
    Clin Lab Haematol; 1991; 13(3):251-3. PubMed ID: 1794227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of body iron stores on the serum erythropoietin concentration in hemodialyzed patients.
    Teruel JL; Marcen R; Navarro JF; Villafruela JJ; Fernandez Lucas M; Rivera M; Ortuño J
    Am J Nephrol; 1994; 14(2):95-8. PubMed ID: 8080013
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Case study of the anemic patient: epoetin alfa--focus on iron management.
    Kirlin LF
    ANNA J; 1995 Apr; 22(2):192-5. PubMed ID: 7786067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The influence of inflammatory markers and CRP predictive value in relation to the target hemoglobin level in patients on chronic hemodialysis.
    Musanovic A; Trnacevic S; Mekic M; Musanovic A
    Med Arch; 2013; 67(5):361-4. PubMed ID: 24601173
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sodium ferric gluconate complex given intravenously for iron deficiency in hemodialysis.
    Pascual J; Teruel JL; Liaño F; Sureda A; Ortuño J
    Clin Nephrol; 1991 Feb; 35(2):87. PubMed ID: 2019020
    [No Abstract]   [Full Text] [Related]  

  • 57. Improved response to erythropoietin therapy with long-term continuous iron supplementation.
    Descombes E; Fellay G
    Nephron; 2000 Feb; 84(2):196-7. PubMed ID: 10657727
    [No Abstract]   [Full Text] [Related]  

  • 58. Effective and safe IV iron and anemia management during home hemodialysis: a dialysis facility's experience.
    Utley M
    Nephrol Nurs J; 2005; 32(6):659-65; quiz 666-7. PubMed ID: 16425811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin.
    Anbu AT; Kemp T; O'donnell K; Smith PA; Bradbury MG
    Acta Paediatr; 2005 Dec; 94(12):1738-41. PubMed ID: 16431410
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anemia management and mortality risk in incident hemodialysis patients.
    Auerbach M
    JAMA; 2010 Jul; 304(1):41-2; author reply 42-3. PubMed ID: 20606145
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.